Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

• Status: Completed
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators propose to perform a randomized clinical trial comparing prasugrel vs. ticagrelor in 60 patients with ST elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. The principal objective of the study would be analyzing the difference in myocardial infarction size measured by cardiac magnetic resonance at 6 months

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AORTICA Group
• Treatments: Prasugrel Hydrochloride; Ticagrelor

Criteria

Inclusion Criteria:

• age 18 years or older and equal or less than 75 years

• symptom onset within 12 hours before random assignment

• chest pain lasting more than 30 minutes

• ST-segment elevation of at least 0.1 mV in at least 2 limb leads, ST-segment elevation of at least 0.2 mV in 2 or more contiguous precordial leads, or left bundle-branch block or paced rhythm

• time from symptoms onset to randomization less than 6 hours

• no severe heart failure (Killip class <3)

• informed, written consent

Exclusion Criteria:

• history of myocardial infarction with Q wave

• history of surgical or percutaneous coronary revascularization

• cardiogenic shock, defined as a systolic blood pressure <90 mm Hg with no response to fluid administration or <100 mm Hg in patients with supportive treatment and no bradycardia

• history of stroke

• history of bronchial asthma

• symtomatic sinusal bradicardia or advance AV block

• history of hypersensitivity to aspirin, prasugrel or ticagrelor or contraindication to the doses established in the study

• patients pretreated with 600 mg of clopidogrel or more

• contraindication for the use of gadolinium during the magenitc resonance